RPRX
Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, holding a diversified portfolio of over 35 commercial products and 20 development-stage candidates spanning therapeutic areas including cystic fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, spinal muscular atrophy, prostate cancer, inflammatory bowel disease, and other major disease areas across modalities such as small molecules, monoclonal antibodies, and antisense oligonucleotides. The portfolio includes commercial stage approvals such as Vertex's Trikafta and Alyftrek for cystic fibrosis, GSK's Trelegy for COPD, Biogen's Tysabri and Spinraza for multiple sclerosis and spinal muscular atrophy respectively, Roche's Evrysdi for spinal muscular atrophy